The Cancer News
AN AUTHORITATIVE RESOURCE FOR EVERYTHING ABOUT CANCER
Cancer Education
Explore expert insights on the fundamentals of cancer, including how it develops, key risk factors, prevention strategies, and treatment options. This section also highlights cancer awareness months and related observance days and weeks. Commentaries from our network of oncology professionals shed light on critical issues that require greater attention across the cancer care and research continuum.
Dr. Chaitra S. Ujjani on B-Cell Lymphoma: Bispecific Antibodies and CAR T-Cell Therapy Updates from ASH
By The Cancer News Team
Expert highlights from Dr. Chaitra S. Ujjani on bispecific antibodies and CAR T-cell therapy in B-cell lymphomas, featuring key efficacy, safety, and practice-changing updates from the 2025 ASH meeting.
Dr. Chaitra S. Ujjani on B-Cell Lymphoma: Bispecific Antibodies and CAR T-Cell Therapy Updates from ASH
By The Cancer News Team
Expert highlights from Dr. Chaitra S. Ujjani on bispecific antibodies and CAR T-cell therapy in B-cell lymphomas, featuring key efficacy, safety, and practice-changing updates from the 2025 ASH meeting.
Dr. Chaitra S. Ujjani on B-Cell Lymphoma: Bispecific Antibodies and CAR T-Cell Therapy Updates from ASH
By The Cancer News Team
Expert highlights from Dr. Chaitra S. Ujjani on bispecific antibodies and CAR T-cell therapy in B-cell lymphomas, featuring key efficacy, safety, and practice-changing updates from the 2025 ASH meeting.
Dr. Ghulam Rehman Mohyuddin on Relapsed/Recurrent Multiple Myeloma: CAR T-Cell Therapy and Bispecific Antibody Strategies
By The Cancer News Team
Dr. Ghulam Rehman Mohyuddin reviews modern treatment strategies for relapsed multiple myeloma, comparing CAR T-cell therapy and bispecific antibodies, with practical guidance on sequencing and patient selection.
Dr. Ghulam Rehman Mohyuddin on Relapsed/Recurrent Multiple Myeloma: CAR T-Cell Therapy and Bispecific Antibody Strategies
By The Cancer News Team
Dr. Ghulam Rehman Mohyuddin reviews modern treatment strategies for relapsed multiple myeloma, comparing CAR T-cell therapy and bispecific antibodies, with practical guidance on sequencing and patient selection.
Dr. Ghulam Rehman Mohyuddin on Relapsed/Recurrent Multiple Myeloma: CAR T-Cell Therapy and Bispecific Antibody Strategies
By The Cancer News Team
Dr. Ghulam Rehman Mohyuddin reviews modern treatment strategies for relapsed multiple myeloma, comparing CAR T-cell therapy and bispecific antibodies, with practical guidance on sequencing and patient selection.
Dr. Akshat Jain on Cancer-Associated Thrombosis: Latest Advances from ASH 2025
By The Cancer News Team
Dr. Akshat Jain reviews key advances in cancer-associated thrombosis from ASH 2025, covering epidemiology, pathophysiology, anticoagulation strategies, and evidence-based guidance for prevention and treatment.
Dr. Akshat Jain on Cancer-Associated Thrombosis: Latest Advances from ASH 2025
By The Cancer News Team
Dr. Akshat Jain reviews key advances in cancer-associated thrombosis from ASH 2025, covering epidemiology, pathophysiology, anticoagulation strategies, and evidence-based guidance for prevention and treatment.
Dr. Akshat Jain on Cancer-Associated Thrombosis: Latest Advances from ASH 2025
By The Cancer News Team
Dr. Akshat Jain reviews key advances in cancer-associated thrombosis from ASH 2025, covering epidemiology, pathophysiology, anticoagulation strategies, and evidence-based guidance for prevention and treatment.
Are We Finally Making Progress Against Triple-Negative Breast Cancer? Dr. Lynn Symonds Weighs In
By The Cancer News Team
Dr. Lynn Symonds reviews recent advances in triple-negative breast cancer, including adjuvant carboplatin, PARP inhibitor combinations, and emerging ADCs—highlighting progress while underscoring persistent unmet needs.
Are We Finally Making Progress Against Triple-Negative Breast Cancer? Dr. Lynn Symonds Weighs In
By The Cancer News Team
Dr. Lynn Symonds reviews recent advances in triple-negative breast cancer, including adjuvant carboplatin, PARP inhibitor combinations, and emerging ADCs—highlighting progress while underscoring persistent unmet needs.
Are We Finally Making Progress Against Triple-Negative Breast Cancer? Dr. Lynn Symonds Weighs In
By The Cancer News Team
Dr. Lynn Symonds reviews recent advances in triple-negative breast cancer, including adjuvant carboplatin, PARP inhibitor combinations, and emerging ADCs—highlighting progress while underscoring persistent unmet needs.
Dr. Michael Snyder on Advances in Genomic Medicine: Multi-Omics Approaches to Cancer Research and AI Applications in Precision Health
By The Cancer News Team
Dr. Michael Snyder of Stanford Medicine discusses how multi-omics research and artificial intelligence are reshaping cancer biology, early detection, and precision health, using familial adenomatous polyposis as a model.
Dr. Michael Snyder on Advances in Genomic Medicine: Multi-Omics Approaches to Cancer Research and AI Applications in Precision Health
By The Cancer News Team
Dr. Michael Snyder of Stanford Medicine discusses how multi-omics research and artificial intelligence are reshaping cancer biology, early detection, and precision health, using familial adenomatous polyposis as a model.
Dr. Michael Snyder on Advances in Genomic Medicine: Multi-Omics Approaches to Cancer Research and AI Applications in Precision Health
By The Cancer News Team
Dr. Michael Snyder of Stanford Medicine discusses how multi-omics research and artificial intelligence are reshaping cancer biology, early detection, and precision health, using familial adenomatous polyposis as a model.
Stanford Medicine Clinicians Highlight How Radiologists, Surgeons, and Pathologists Can Advance Precision Oncology Treatment
By The Cancer News Team
Stanford Medicine experts discuss how radiology, surgery, and pathology inform precision oncology, highlighting imaging phenotypes, treatment response assessment, and opportunities for surgical de-escalation in breast cancer care.
Stanford Medicine Clinicians Highlight How Radiologists, Surgeons, and Pathologists Can Advance Precision Oncology Treatment
By The Cancer News Team
Stanford Medicine experts discuss how radiology, surgery, and pathology inform precision oncology, highlighting imaging phenotypes, treatment response assessment, and opportunities for surgical de-escalation in breast cancer care.
Stanford Medicine Clinicians Highlight How Radiologists, Surgeons, and Pathologists Can Advance Precision Oncology Treatment
By The Cancer News Team
Stanford Medicine experts discuss how radiology, surgery, and pathology inform precision oncology, highlighting imaging phenotypes, treatment response assessment, and opportunities for surgical de-escalation in breast cancer care.
Dr. Stephen B. Gruber on Germline Genetic Testing in Cancer Treatment Drag
By The Cancer News Team
Dr. Stephen B. Gruber discusses how germline genetic testing shapes cancer therapy selection, reveals gaps in current guidelines, and presents INSPIRE study data supporting universal access to comprehensive genetic testing.
Dr. Stephen B. Gruber on Germline Genetic Testing in Cancer Treatment Drag
By The Cancer News Team
Dr. Stephen B. Gruber discusses how germline genetic testing shapes cancer therapy selection, reveals gaps in current guidelines, and presents INSPIRE study data supporting universal access to comprehensive genetic testing.
Dr. Stephen B. Gruber on Germline Genetic Testing in Cancer Treatment Drag
By The Cancer News Team
Dr. Stephen B. Gruber discusses how germline genetic testing shapes cancer therapy selection, reveals gaps in current guidelines, and presents INSPIRE study data supporting universal access to comprehensive genetic testing.
Attorney Henry T. Greely on Navigating Ethical Challenges in Precision Oncology
By The Cancer News Team
A multidisciplinary panel led by Stanford ethicist Henry T. Greely, JD, examines the ethical challenges of precision oncology, including informed consent, access disparities, privacy concerns, and real-world clinical decision-making.
Attorney Henry T. Greely on Navigating Ethical Challenges in Precision Oncology
By The Cancer News Team
A multidisciplinary panel led by Stanford ethicist Henry T. Greely, JD, examines the ethical challenges of precision oncology, including informed consent, access disparities, privacy concerns, and real-world clinical decision-making.
Attorney Henry T. Greely on Navigating Ethical Challenges in Precision Oncology
By The Cancer News Team
A multidisciplinary panel led by Stanford ethicist Henry T. Greely, JD, examines the ethical challenges of precision oncology, including informed consent, access disparities, privacy concerns, and real-world clinical decision-making.
Liquid Biopsy in Oncology: What Clinicians Are Actually Saying
By The Cancer News Team
A multidisciplinary panel of oncology experts discusses real-world use of liquid biopsy, comparing it with tissue biopsy and exploring clonal hematopoiesis, tumor-informed assays, minimal residual disease testing, and circulating tumor DNA.
Liquid Biopsy in Oncology: What Clinicians Are Actually Saying
By The Cancer News Team
A multidisciplinary panel of oncology experts discusses real-world use of liquid biopsy, comparing it with tissue biopsy and exploring clonal hematopoiesis, tumor-informed assays, minimal residual disease testing, and circulating tumor DNA.
Liquid Biopsy in Oncology: What Clinicians Are Actually Saying
By The Cancer News Team
A multidisciplinary panel of oncology experts discusses real-world use of liquid biopsy, comparing it with tissue biopsy and exploring clonal hematopoiesis, tumor-informed assays, minimal residual disease testing, and circulating tumor DNA.
Highlights of ASCO Gastrointestinal Cancer Symposium 2026: From Bench to Bedside
By Dr. Meghana Singh
Key clinical trial highlights from ASCO GI 2026, covering practice-changing data in gastric, colorectal, pancreatic, and liver cancers, including HERIZON GEA-01, ILLUSTRO, COMMIT II, and BREAKWATER.
Highlights of ASCO Gastrointestinal Cancer Symposium 2026: From Bench to Bedside
By Dr. Meghana Singh
Key clinical trial highlights from ASCO GI 2026, covering practice-changing data in gastric, colorectal, pancreatic, and liver cancers, including HERIZON GEA-01, ILLUSTRO, COMMIT II, and BREAKWATER.
Highlights of ASCO Gastrointestinal Cancer Symposium 2026: From Bench to Bedside
By Dr. Meghana Singh
Key clinical trial highlights from ASCO GI 2026, covering practice-changing data in gastric, colorectal, pancreatic, and liver cancers, including HERIZON GEA-01, ILLUSTRO, COMMIT II, and BREAKWATER.